Can a knee injection regrow cartilage? new trial tests LRX712
NCT ID NCT04097379
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested an experimental drug called LRX712, given as injections into the knee, to see if it can help regrow cartilage in people with mild to moderate knee osteoarthritis. 45 participants received either the drug or a placebo over 8 weeks. The main goal was to measure changes in cartilage volume using advanced MRI scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- LRX712 (injected into the knee joint)
- What this could lead to
- If it works, this could point toward a treatment that repairs cartilage and slows knee osteoarthritis.
- What could go wrong
- This is a small, early-phase trial with only 45 people. The drug may not work better than placebo, and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS (OA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Leiden, South Holland, 2333 CL, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Virtual program aims to keep joint replacement patients moving while they wait
- MuseCells under the microscope: 5-Year registry tracks Real-World outcomes
- Simple blood test could spot osteoarthritis years earlier
- Can a single online class ease severe arthritis pain?
- Robot vs surgeon: which knee replacement works better?
- Can weak muscles slow down hip surgery recovery? new study aims to find out